Eddie Hickman
Stock Analyst at Guggenheim
(4.69)
# 854
Out of 4,683 analysts
53
Total ratings
73.9%
Success rate
36.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Reiterated: Buy | $69 → $100 | $14.46 | +591.56% | 8 | Aug 14, 2026 | |
| ZVRA Zevra Therapeutics | Maintained: Buy | $24 → $23 | $11.74 | +95.91% | 9 | Aug 6, 2026 | |
| GHRS GH Research | Reiterated: Buy | $34 → $40 | $29.01 | +37.88% | 5 | Aug 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintained: Buy | $90 → $89 | $70.65 | +25.97% | 16 | Jul 21, 2026 | |
| ATAI AtaiBeckley | Downgraded: Hold | n/a | $7.39 | - | 3 | Jul 16, 2026 | |
| HELP Cybin | Maintained: Buy | $39 → $48 | $13.63 | +252.16% | 3 | Dec 3, 2025 | |
| OTLK Outlook Therapeutics | Downgraded: Hold | n/a | $0.6233 | - | 7 | Aug 28, 2025 | |
| IMVT Immunovant | Reiterated: Buy | $44 | $43.89 | n/a | 2 | Aug 11, 2025 |
ProMIS Neurosciences
Aug 14, 2026
Reiterated: Buy
Price Target: $69 → $100
Current: $14.46
Upside: +591.56%
Zevra Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $24 → $23
Current: $11.74
Upside: +95.91%
GH Research
Aug 6, 2026
Reiterated: Buy
Price Target: $34 → $40
Current: $29.01
Upside: +37.88%
Tarsus Pharmaceuticals
Jul 21, 2026
Maintained: Buy
Price Target: $90 → $89
Current: $70.65
Upside: +25.97%
AtaiBeckley
Jul 16, 2026
Downgraded: Hold
Price Target: n/a
Current: $7.39
Upside: -
Cybin
Dec 3, 2025
Maintained: Buy
Price Target: $39 → $48
Current: $13.63
Upside: +252.16%
Outlook Therapeutics
Aug 28, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.6233
Upside: -
Immunovant
Aug 11, 2025
Reiterated: Buy
Price Target: $44
Current: $43.89
Upside: n/a